BMPR2 and fragile X syndrome: Notably, context-specific effects of TGF-β/BMP signaling must be considered; for example, BMPRII loss promotes PAH, whereas gain-of-function contributes to FXS, underscoring the need for tissue-specific therapeutic modulation.